XTLB (XTL Biopharmaceuticals) Institutional Ownership: 3.07% (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTLB XTL Biopharmaceuticals Ltd XTLB
22 GF Score
Price $2.96
! 4 Warning Signs
View Full Analysis

What is XTL Biopharmaceuticals Institutional Ownership?

XTL Biopharmaceuticals XTLB +2.25% 22 Institutional Ownership is 3.07% as of Jul. 14, 2026. GuruFocus rates XTLB with a GF Score™ of 22/100. The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, XTL Biopharmaceuticals's institutional ownership is 3.07%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, XTL Biopharmaceuticals's Insider Ownership is 0.17%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, XTL Biopharmaceuticals's Float Percentage Of Total Shares Outstanding is 75.07%.

XTL Biopharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for XTL Biopharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals Institutional Ownership Chart

XTL Biopharmaceuticals Historical Data

The historical data trend for XTL Biopharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.10 0.10 0.10 0.10 0.09 0.09 0.09 0.10 0.09 0.09
XTLB
22GF Score
XTL Biopharmaceuticals Ltd XTLB
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XTL Biopharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 3.07% mean?
XTL Biopharmaceuticals (XTLB) has a Institutional Ownership of 3.07% as of Jul. 14, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on XTL Biopharmaceuticals and its competitors.
Is XTL Biopharmaceuticals' Institutional Ownership too high?
XTL Biopharmaceuticals' current Institutional Ownership is 3.07%. Overall, XTL Biopharmaceuticals has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' Institutional Ownership compare to VRTX and REGN?
XTL Biopharmaceuticals' Institutional Ownership of 3.07% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on XTL Biopharmaceuticals and its competitors. XTL Biopharmaceuticals's current Institutional Ownership is 3.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current Institutional Ownership of 3.07%. The current Institutional Ownership is 3.07%. XTL Biopharmaceuticals' overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current Institutional Ownership is 3.07% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XTL Biopharmaceuticals Business Description

Other Exchanges XTLB:IsraelHHB0:Germany
Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
22GF Score

Get the complete analysis for XTLB

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.96
Price